-
Product Insights
NewLikelihood of Approval Analysis for Insomnia
Overview How likely is it that the drugs in Insomnia will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Insomnia Overview Insomnia is a sleep disorder that is characterized by difficulty falling...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tasimelteon in Insomnia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tasimelteon in Insomnia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tasimelteon in Insomnia Drug Details: Tasimelteon (Hetlioz) is a derivative of benzofuran acts...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OPL-053 in Insomnia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OPL-053 in Insomnia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OPL-053 in Insomnia Drug Details: OPL-053 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lumateperone Tosylate in Insomnia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lumateperone Tosylate in Insomnia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lumateperone Tosylate in Insomnia Drug Details: Lumateperone tosylate (Caplyta) is a butyrophenone...
-
Product Insights
Insomnia – Drugs In Development, 2023
Global Markets Direct’s, ‘Insomnia - Drugs In Development, 2023’, provides an overview of the Insomnia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Insomnia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cannabidiol + Cannabinol + Tetrahydrocannabinol) in Insomnia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cannabidiol + Cannabinol + Tetrahydrocannabinol) in Insomnia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cannabidiol + Cannabinol + Tetrahydrocannabinol) in Insomnia Drug Details:...
-
Sector Analysis
Insomnia Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Insomnia Market Report Overview The Insomnia market across the 7MM (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) was valued at $3.2 billion in 2022. Steady growth is anticipated at a CAGR of more than 2% from 2022 to 2032, due to the launch of four novel pipeline agents - Hetlioz, SM-1, vornorexant, and sunobinop. The insomnia market research report offers an overview of insomnia, including its epidemiology, symptoms, diagnosis, and disease management. The report offers key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cannabidiol in Insomnia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cannabidiol in Insomnia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cannabidiol in Insomnia Drug Details: Cannabidiol is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sunobinop Tosylate in Insomnia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sunobinop Tosylate in Insomnia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sunobinop Tosylate in Insomnia Drug Details: Sunobinop is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tasipimidine in Insomnia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tasipimidine in Insomnia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tasipimidine in Insomnia Drug Details: Tasipimidine is under development for the treatment of...